SESSION TITLE: Airways 1
SESSION TYPE: Original Investigation Poster
PRESENTED ON: Wednesday, October 26, 2016 at 01:30 PM - 02:30 PM
PURPOSE: Revefenacin (pINN), a novel nebulized long-acting muscarinic antagonist (LAMA) in development for chronic obstructive pulmonary disease (COPD), produces sustained bronchodilation with minimal systemic anticholinergic effects. A 28-day phase 2b study in participants with COPD demonstrated that doses of 88 and 175 µg, administered once daily, produced clinically relevant changes compared with placebo across a range of endpoints. To establish efficacy and safety for this dose range, 2 identical 12-week phase 3 efficacy trials in participants with COPD are in progress; the trial methodology and select characteristics of the participants enrolled to-date are presented here.